2022
33933 Relationship between skin involvement and disease burden in patients with mild to moderate plaque psoriasis: Real-world findings From CorEvitas’ Psoriasis Registry
Ogdie A, Strober B, Lebwohl M. 33933 Relationship between skin involvement and disease burden in patients with mild to moderate plaque psoriasis: Real-world findings From CorEvitas’ Psoriasis Registry. Journal Of The American Academy Of Dermatology 2022, 87: ab103. DOI: 10.1016/j.jaad.2022.06.444.Peer-Reviewed Original Research
2021
26085 Key efficacy and safety of apremilast in patients with mild to moderate plaque psoriasis in the phase 3 ADVANCE trial
Duffin K, Gold L, Leonardi C, Pariser D, Green L, Sofen H, Strober B, Chen M, Wang A, Papp K. 26085 Key efficacy and safety of apremilast in patients with mild to moderate plaque psoriasis in the phase 3 ADVANCE trial. Journal Of The American Academy Of Dermatology 2021, 85: ab83. DOI: 10.1016/j.jaad.2021.06.356.Peer-Reviewed Original ResearchSafety of apremilastModerate plaque psoriasisADVANCE trialPlaque psoriasisKey efficacyPsoriasisPatientsApremilast27876 The PASI-HD improved precision in measuring disease severity in subjects with mild to moderate plaque psoriasis treated with roflumilast cream, a phosphodiesterase-4 inhibitor
Papp K, Lebwohl M, Kircik L, Pariser D, Strober B, Krueger G, Berk D, Navale L, Higham R. 27876 The PASI-HD improved precision in measuring disease severity in subjects with mild to moderate plaque psoriasis treated with roflumilast cream, a phosphodiesterase-4 inhibitor. Journal Of The American Academy Of Dermatology 2021, 85: ab164. DOI: 10.1016/j.jaad.2021.06.670.Peer-Reviewed Original Research
2019
Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study
Strober B, Alikhan A, Lockshin B, Shi R, Cirulli J, Schafer P. Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study. Journal Of Dermatological Science 2019, 96: 126-133. PMID: 31787506, DOI: 10.1016/j.jdermsci.2019.09.003.Peer-Reviewed Original ResearchConceptsModerate plaque psoriasisIL-17APlaque psoriasisIL-22Week 16T cellsRegulatory T cell numbersT helper 17 (Th17) cellsEfficacy of apremilastIL-23 levelsTotal T cellsPlasma cytokine levelsRegulatory T cellsT cell numbersMedian percentage reductionPathogenesis of psoriasisSevere psoriasisCardiometabolic biomarkersClinical improvementCytokine levelsInflammatory biomarkersIL-17FWeeks 0Clinical trialsWeek 4
2017
Efficacy and Safety of Apremilast in Patients with Moderate Plaque Psoriasis with Lower BSA (UNVEIL Phase IV Study)
Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson J, Goncalves J, Levi E, Callis Duffin K. Efficacy and Safety of Apremilast in Patients with Moderate Plaque Psoriasis with Lower BSA (UNVEIL Phase IV Study). SKIN The Journal Of Cutaneous Medicine 2017, 1: s11. DOI: 10.25251/skin.1.supp.10.Peer-Reviewed Original ResearchSafety of apremilastModerate plaque psoriasisPlaque psoriasisLower BSAPsoriasisPatientsApremilastCelgeneEfficacy of Apremilast on Quality-of-Life Measures in Patients with Moderate Plaque Psoriasis (UNVEIL Phase IV Study)
Bagel J, Lebwohl M, Stein Gold L, Jackson J, Goncalves J, Levi E, Callis Duffin K, Strober B. Efficacy of Apremilast on Quality-of-Life Measures in Patients with Moderate Plaque Psoriasis (UNVEIL Phase IV Study). SKIN The Journal Of Cutaneous Medicine 2017, 1: s13. DOI: 10.25251/skin.1.supp.12.Peer-Reviewed Original ResearchEfficacy of apremilastModerate plaque psoriasisPlaque psoriasisLife measuresPsoriasisPatientsApremilastCelgeneEfficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson J, Chen R, Goncalves J, Levi E, Callis Duffin K. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. Journal Of Drugs In Dermatology 2017, 16: 801-808. PMID: 28809995.Peer-Reviewed Original ResearchConceptsModerate plaque psoriasisSafety of apremilastPlaque psoriasisGlobal assessment scoreStatic Physician's Global Assessment scoreDermatology Life Quality Index scoresUpper respiratory tract infectionPhysician Global Assessment scoreLife Quality Index scoresPercentage changePrior topical therapyMost adverse eventsPrimary efficacy endpointSevere plaque psoriasisTreatment Satisfaction QuestionnaireRespiratory tract infectionsHigh patient satisfactionMean percentage changeQuality Index scoresQuality of lifeGreater percentage changeEfficacy endpointAdverse eventsTopical therapyTract infections